Inhibition of CCR7 induced PI3K/AKT signaling and MAPK signaling with Ly294002 (PI3K inhibitor) and PD98059 (MEK inhibitor) demonstrated that Ly294002 also impaired the CCL21 induced MAPKp42/44 phosphorylation in HS578T-Hyg breast cancer cells, M13SV1-EGFP-Neo breast epithelial cells exhibiting stem cell properties and M13HS-2 hybrid cells. This evidence concerns the gene MAP2K7 and breast carcinoma.